1. 首页
  2. 抗体
  3. 正文

BD Pharmingen- FITC Rat Anti-Human IL-6_BD Pharmingen

艾美捷科技 • 2025年08月22日 11:09:05 • 抗体 • 阅读 17 • 标签
产品信息
荧光素标记
FITC
抗原名称
IL-6
宿主
Rat IgG1
免疫原
Human IL-6 Recombinant Protein
简单描述
The MQ2-13A5 monoclonal antibody specifically binds to human interleukin-6 (IL-6). IL-6 is a multifunctional cytokine that plays a central role in host defense mechanisms, including hematopoiesis, immune responses (eg, T and B cell activation and differentiation) and acute phase reactions. IL-6 can be expressed by a variety of cells including monocytes/macrophages, eosinophils, fibroblasts, vascular endothelial cells, bone marrow stromal cells, mesangial cells, hepatocytes, keratinocytes, astrocytes, T lymphocytes, B lymphocytes, and various tumor cells. IL-6 production is upregulated by cells in response to bacterial products such as lipopolysaccharide, viruses and other pro-inflammatory cytokines such as IL-1, TNF , and IFN-γ. IL-6 transcription is downregulated by cells in response to IL-4 and IL-10. The functional IL-6 Receptor (IL-6R) complex consists of two transmembrane glycoproteins, an 80-kDa low-affinity ligand-binding receptor subunit (IL-6Rα/CD126) and a 130 kDa (gp130/CD130) subunit that binds to IL-6-IL-6Rα to form the high-affinity signal transducing complex. Abnormal expression of IL-6 is related to the pathogenesis of many diseases including neoplastic (eg, multiple myeloma) and autoimmune diseases (eg, rheumatoid arthritis). The immunogen used to generate this hybridoma was COS-7 -expressed recombinant human IL-6. This antibody is routinely tested by flow cytometric analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.
商品描述
MQ2-13A5 The MQ2-13A5 monoclonal antibody specifically binds to human interleukin-6 (IL-6). IL-6 is a multifunctional cytokine that plays a central role in host defense mechanisms, including hematopoiesis, immune responses (eg, T and B cell activation and differentiation) and acute phase reactions. IL-6 can be expressed by a variety of cells including monocytes/macrophages, eosinophils, fibroblasts, vascular endothelial cells, bone marrow stromal cells, mesangial cells, hepatocytes, keratinocytes, astrocytes, T lymphocytes, B lymphocytes, and various tumor cells. IL-6 production is upregulated by cells in response to bacterial products such as lipopolysaccharide, viruses and other pro-inflammatory cytokines such as IL-1, TNF , and IFN-γ. IL-6 transcription is downregulated by cells in response to IL-4 and IL-10. The functional IL-6 Receptor (IL-6R) complex consists of two transmembrane glycoproteins, an 80-kDa low-affinity ligand-binding receptor subunit (IL-6Rα/CD126) and a 130 kDa (gp130/CD130) subunit that binds to IL-6-IL-6Rα to form the high-affinity signal transducing complex. Abnormal expression of IL-6 is related to the pathogenesis of many diseases including neoplastic (eg, multiple myeloma) and autoimmune diseases (eg, rheumatoid arthritis). The immunogen used to generate this hybridoma was COS-7 -expressed recombinant human IL-6. This antibody is routinely tested by flow cytometric analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.
同种型
Rat IgG1
克隆号
克隆 MQ2-13A5 (RUO)
浓度
0.5 mg/ml
产品详情
FITC
Fluorescein (FITC) is part of the BD blue family of dyes. This is a small organic fluorochrome with an excitation maximum (Ex Max) at 494-nm and an emission maximum (Em Max) at 518-nm. FITC is designed to be excited by the Blue laser (488-nm) and detected using an optical filter centered near 520 nm (e.g., a 530/30-nm bandpass filter). Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
FITC
Blue 488 nm
494 nm
518 nm
应用
实验应用
Intracellular staining (flow cytometry) (Routinely Tested)
反应种属
Human (QC Testing)
目标/特异性
IL-6
制备和贮存
存储溶液
Aqueous buffered solution containing ≤0.09% sodium azide.
保存方式
Aqueous buffered solution containing ≤0.09% sodium azide.
文献
文献
研发参考(4) 1. Abrams J. Immunoenzymetric assay of mouse and human cytokines using NIP-labeled anti-cytokine antibodies. Curr Protoc Immunol. 2001; 1:6.20-6.21. (Clone-specific: ELISA, Neutralization). 2. Abrams JS, Roncarolo MG, Yssel H, Andersson U, Gleich GJ, Silver JE. Strategies of anti-cytokine monoclonal antibody development: immunoassay of IL-10 and IL-5 in clinical samples. Immunol Rev. 1992; 127:5-24. (Clone-specific: ELISA, Neutralization). 3. Gaines Das RE, Poole S. The international standard for interleukin-6. Evaluation in an international collaborative study. J Immunol Methods. 1993; 160(2):147-153. (Clone-specific: ELISA, Neutralization). 4. Prussin C, Metcalfe DD. Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J Immunol Methods. 1995; 188(1):117-128. (Methodology: IC/FCM Block).

参考图片

Expression of IL-6 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS (100 ng/ml final concentration) in the presence of GolgiStop™ (2 µM final concentration; Cat. No. 554724). The PBMC were harvested, stained with PE-mouse anti-human CD14 monoclonal antibody (PE-M5E2, Cat. No. 555398), fixed, permeabilized, and subsequently stained with 0.25 µg of FITC-rat anti-human IL-6 antibody (Cat. No. 554544), following Pharmingen's staining protocol (left panel). The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, the binding by FITC-MQ2-13A5 antibody was blocked by each of the following: 1) preincubation of the fluorochrome-conjugated antibody with molar excess of recombinant human IL-6 (0.5 µg, Cat. No. 550071; (middle panel) and by 2) preincubation of the fixed/permeabilized cells with excess unlabeled MQ2-13A5 antibody (e.g., 5 µg; Cat. No. 554543; right panel) prior to staining with the FITC-MQ2-13A5 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the recombinant cytokine blocking and unlabeled antibody blocking specificity controls.

Expression of IL-6 by stimulated CD14+ human monocytes. Human PBMC were stimulated for 6 hours with LPS (100 ng/ml final concentration) in the presence of GolgiStop™ (2 µM final concentration; Cat. No. 554724). The PBMC were harvested, stained with PE-mouse anti-human CD14 monoclonal antibody (PE-M5E2, Cat. No. 555398), fixed, permeabilized, and subsequently stained with 0.25 µg of FITC-rat anti-human IL-6 antibody (Cat. No. 554544), following Pharmingen's staining protocol (left panel). The data reflect gating on monocytes, based on forward and side scattered light signals. To demonstrate specificity of staining, the binding by FITC-MQ2-13A5 antibody was blocked by each of the following: 1) preincubation of the fluorochrome-conjugated antibody with molar excess of recombinant human IL-6 (0.5 µg, Cat. No. 550071; (middle panel) and by 2) preincubation of the fixed/permeabilized cells with excess unlabeled MQ2-13A5 antibody (e.g., 5 µg; Cat. No. 554543; right panel) prior to staining with the FITC-MQ2-13A5 antibody. The quadrant markers for the bivariate dot plots were set based on the autofluorescence controls and verified using the recombinant cytokine blocking and unlabeled antibody blocking specificity controls.

文档下载: W 导出为BD Pharmingen- FITC Rat Anti-Human IL-6_BD Pharmingen.doc文档

本文来自投稿，不代表本人立场，如若转载，请注明出处：http://www.iamyjet.com/kangti/9649.html

赞 (17)
打赏 微信扫一扫
« 上一篇 2025年08月22日 11:08:43
下一篇 » 2025年08月22日 11:09:57

相关推荐

×
(function(){ var src = (document.location.protocol == "http:") ? "http://js.passport.qihucdn.com/11.0.1.js?1d7dde81dc0903e04d3ac0b9599444f6":"https://jspassport.ssl.qhimg.com/11.0.1.js?1d7dde81dc0903e04d3ac0b9599444f6"; document.write('<\/mip-script>'); })(); (function(){ var bp = document.createElement('script'); var curProtocol = window.location.protocol.split(':')[0]; if (curProtocol === 'https') { bp.src = 'https://zz.bdstatic.com/linksubmit/push.js'; } else { bp.src = 'http://push.zhanzhang.baidu.com/push.js'; } var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(bp, s); })();